NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors.

Originally posted here:

Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *